Le Lézard
Classified in: Health
Subjects: PET, ANW, FVT

The Maker of NexGard® (afoxolaner) and North Shore Animal League America are Celebrating the Dog Days of Summer on "DOGust the 1st" With a Mobile Pet Adoption Event


NEW YORK, July 25, 2017 /PRNewswire/ -- In celebration of DOGust the 1st-- the universal birthday for shelter and rescue dogs, since most often their actual dates of birth are unknown--the NexGard® (afoxolaner) team and North Shore Animal League America (NSALA) are teaming up to host a one-of-a-kind birthday party in New York City.

The NexGard team will sponsor the first 20 dog adoptions for all approved adopters at the event, and will provide dozens of pet toys to NSALA so dogs at the shelter will receive birthday gifts on DOGust the 1st.

"Birthday parties are synonymous with love, gratitude and joy, sentiments which every dog ? even if awaiting a forever home ? should be able to experience," said Mike Hutton, Head of U.S. Pet Vet Marketing at Boehringer Ingelheim. "In addition to bringing these dogs joy for a day, the NexGard team is proud to help raise awareness of the importance of pet adoption and the great work that North Shore Animal League of America does in order to achieve our common goal of keeping more dogs happy, healthy and in loving homes."

The birthday party will take place at Columbus Circle, between Central Park West and Broadway, on August 1, 2017 from 3 - 8 p.m.

"When we created DOGust the 1st in 2009, we could only dream that it would grow to be as popular as it has become in raising awareness for the plight of homeless animals," said Joanne Yohannan, Senior Vice President, Operations, NSALA. "The adorable, adoptable dogs in our care are so deserving of this celebration, and thanks to the NexGard team's adoption sponsorship, we will be able to continue rescuing and finding responsible homes for even more dogs."

DOGust the 1st guests who adopt during the birthday party will have the opportunity to enter an on-site sweepstakes for a chance to win up to $500 toward their It's a Dog! pet gift registry items. Three lucky dog adopters will win!

The NexGard team launched the It's a Dog! online gift registry in April to celebrate the joyous act of adding a dog to a household. At ItsADog.com, new and experienced dog owners can create a pet profile, customize a pet gift registry, enter for a chance to win prizes, and learn important information about dog ownership.

NexGard is the number one veterinarian-recommended flea and tick control product1, and is safe for use in puppies as young as eight weeks weighing four pounds or more. NexGard is a soft, beef-flavored chew that kills both fleas and ticks for a full 30 days ? and dogs love it!2

IMPORTANT SAFETY INFORMATION
NexGard is for use in dogs only. The most frequently reported adverse reactions include vomiting, itching, diarrhea, lethargy and lack of appetite. The safe use of NexGard in pregnant, breeding or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures. For more information, contact your veterinarian or see the prescribing information

About North Shore Animal League America
North Shore Animal League America?the world's largest no-kill rescue and adoption organization?has saved the lives of over 1 million dogs, cats, puppies and kittens at risk of euthanasia. Through our many innovative programs, we reach across the country to rescue animals from overcrowded shelters, unwanted litters, puppy mills, natural disasters and other emergencies and find them responsible, loving homes. As a leader in the no-kill movement, we are dedicated to promoting shelter pet adoptions; encouraging spay/neuter programs; reducing animal cruelty; ending euthanasia; and advancing the highest standards in animal welfare. Please join us in saving the lives of innocent animals by donating to support our lifesaving mission.  Follow us on Facebook: North Shore Animal League America, Twitter: @AnimalLeague & Instagram: @AnimalLeague or visit our website at AnimalLeague.org.

About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.

Boehringer Ingelheim
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry's top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Sources:

(1) Data on file at Merial.

(2) Data on file at Merial.

®NexGard is a registered trademark of Merial. All other trademarks are the property of their respective owners.
©2017 Merial, Inc. Duluth, GA. All rights reserved. Merial is now a part of Boehringer Ingelheim. [DOGUST1PR] (7/17)

SOURCE Boehringer Ingelheim


These press releases may also interest you

18 avr 2024
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The report titled "Progressive Familial Intrahepatic Cholestasis Treatment Market by Drug Type (Cholestyramine, Rifampicin, Ursodeoxycholic Acid), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global...

18 avr 2024
RevolKa Ltd. (Norio Hamamatsu, President & CEO), a venture-backed biotech company providing a game-changing protein engineering technology platform and La Jolla Institute for Immunology (LJI) (Erica Saphire, President & CEO) agreed to start a...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: